In A Press Release Late Wednesday, BioCity Announced A Collaboration Agreement With AstraZeneca On BC3402, A Monoclonal Antibody Targeting Anti-TIM-3, In Combination With IMFINZI (durvalumab) For he Treatment Of Advanced Hepatocellular Carcinoma In China
Portfolio Pulse from Charles Gross
BioCity Biopharma and AstraZeneca have entered into a collaboration agreement to conduct a Phase Ib/II clinical study in China. The study will evaluate the safety and efficacy of BioCity's BC3402 in combination with AstraZeneca's IMFINZI for the treatment of advanced hepatocellular carcinoma. BioCity will lead the trial, which has received IND approval by the National Medical Products Administration.
September 28, 2023 | 8:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's collaboration with BioCity on a clinical study for advanced hepatocellular carcinoma treatment in China could potentially enhance its product portfolio and market presence in China.
The collaboration with BioCity allows AstraZeneca to potentially expand its product portfolio with a new treatment for advanced hepatocellular carcinoma. This could enhance its market presence in China, a major market for healthcare products. The positive impact is based on the potential success of the clinical study and subsequent product approval.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80